{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:02:54Z","timestamp":1789552974596,"version":"build-2803163510"},"reference-count":236,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>The identification of somatic drivers has turned a field once based on morphology into a set of molecular pathways that can potentially be targeted with drugs. Vascular lesions of the eye and ocular adnexa used to be classified by their appearance; many of them are now defined by a post-zygotic variant in a signaling cascade for which an inhibitor is already available. This review groups these lesions by signaling axis and examines how close each pathway is to clinical application. Belzutifan seems to be the most advanced. In a single-arm phase 2 subgroup with prospectively graded retinal endpoints, HIF-2\u03b1 inhibition improved all 16 evaluable eyes in 12 participants, without a comparator arm. PI3K and mTOR inhibition is supported by clinical studies in predominantly non-ocular venous and lymphatic malformations, with more consistent evidence for symptomatic benefit than for volume reduction. Direct orbital evidence remains limited to small series. MEK inhibition treats RAS-driven disease in other locations, but it can also cause a retinopathy of its own, which makes it both a therapy and an ophthalmic concern. Gq\/11 signaling accounts for most capillary malformations, Sturge\u2013Weber syndrome and both choroidal hemangiomas, which are separated by the mutated codon rather than by histology, and it remains a preclinical target. Junctional GJA4 signaling defines the orbital cavernous venous malformation, probably the clearest example of a disease defined by its driver. Genotyping of ocular lesions is limited by tissue access and by variant allele frequencies that are commonly missed by standard panels.<\/jats:p>","DOI":"10.3390\/ijms27188244","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:06:37Z","timestamp":1789549597000},"page":"8244","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Somatic Driver to Molecular Therapy in Retinal, Choroidal and Periocular Vascular Disease: Mosaicism, Targetable Pathways and Ocular Toxicity"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1472-7396","authenticated-orcid":false,"given":"Wojciech","family":"Adamski","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The Regional Hospital in Poznan, The Greater Poland Specialist Center, 60-479 Poznan, Poland"},{"name":"Laboratory of Vision Science and Optometry, Faculty of Physics and Astronomy, Adam Mickiewicz University, 61-614 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1542\/peds.2014-3673","article-title":"Vascular Anomalies Classification: Recommendations from the International Society for the Study of Vascular Anomalies","volume":"136","author":"Wassef","year":"2015","journal-title":"Pediatrics"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kunimoto, K., Yamamoto, Y., and Jinnin, M. (2022). ISSVA Classification of Vascular Anomalies and Molecular Biology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042358"},{"key":"ref_3","first-page":"e113","article-title":"A living document from the International Society for the Study of Vascular Anomalies Classification Group","volume":"6","author":"Goldenberg","year":"2025","journal-title":"J. Vasc. Anom."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"709e","DOI":"10.1097\/PRS.0000000000004294","article-title":"Vascular Anomalies: From a Clinicohistologic to a Genetic Framework","volume":"141","author":"Greene","year":"2018","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/hematology.2024000598","article-title":"Molecular landscape and classification of vascular anomalies","volume":"2024","author":"Seront","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/his.15374","article-title":"Advances in vascular anomalies: Refining classification in the molecular era","volume":"86","author":"Putra","year":"2025","journal-title":"Histopathology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"iyad077","DOI":"10.1093\/genetics\/iyad077","article-title":"Developmental expression of the Sturge-Weber syndrome-associated genetic mutation in Gnaq: A formal test of Happle\u2019s paradominant inheritance hypothesis","volume":"224","author":"Galeffi","year":"2023","journal-title":"Genetics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13023-024-03196-9","article-title":"Assessment of gene-disease associations and recommendations for genetic testing for somatic variants in vascular anomalies by VASCERN-VASCA","volume":"19","author":"Revencu","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2314829","DOI":"10.1001\/jamanetworkopen.2023.14829","article-title":"Barriers to Genetic Testing in Vascular Malformations","volume":"6","author":"Borst","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ajhg.2016.03.009","article-title":"Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma","volume":"98","author":"Ayturk","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1056\/NEJMoa1213507","article-title":"Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ","volume":"368","author":"Shirley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77e","DOI":"10.1097\/PRS.0000000000001868","article-title":"Endothelial Cells from Capillary Malformations Are Enriched for Somatic GNAQ Mutations","volume":"137","author":"Couto","year":"2016","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10456-022-09846-5","article-title":"Somatic GJA4 gain-of-function mutation in orbital cavernous venous malformations","volume":"26","author":"Hongo","year":"2023","journal-title":"Angiogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humpath.2022.10.002","article-title":"A clinicopathological reappraisal of orbital vascular malformations and distinctive GJA4 mutation in cavernous venous malformations","volume":"130","author":"Chen","year":"2022","journal-title":"Hum. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nm.1877","article-title":"Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma","volume":"14","author":"Jinnin","year":"2008","journal-title":"Nat. Med."},{"key":"ref_16","first-page":"2592","article-title":"Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice","volume":"118","author":"Khan","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_17","first-page":"559","article-title":"A unique microvascular phenotype shared by juvenile hemangiomas and human placenta","volume":"137","author":"North","year":"2001","journal-title":"Arch. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/jhg.2014.95","article-title":"The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome","volume":"59","author":"Nakashima","year":"2014","journal-title":"J. Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22985","DOI":"10.1038\/srep22985","article-title":"Ultra-sensitive droplet digital PCR for detecting a low-prevalence somatic GNAQ mutation in Sturge-Weber syndrome","volume":"6","author":"Uchiyama","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.jid.2024.01.033","article-title":"Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV)","volume":"144","author":"Queisser","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10456-016-9538-1","article-title":"A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth","volume":"20","author":"Couto","year":"2017","journal-title":"Angiogenesis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ped4.12424","article-title":"Somatic GNA11\/GNAQ variants in a cohort of Chinese children with Phakomatosis pigmentovascularis","volume":"8","author":"Zhang","year":"2024","journal-title":"Pediatr. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jid.2015.11.027","article-title":"Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis","volume":"136","author":"Thomas","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/ene.15452","article-title":"GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features","volume":"29","author":"Dompmartin","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2016.10.010","article-title":"Somatic GNAQ Mutation is Enriched in Brain Endothelial Cells in Sturge-Weber Syndrome","volume":"67","author":"Huang","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/jamaophthalmol.2018.5141","article-title":"Association of Somatic GNAQ Mutation with Capillary Malformations in a Case of Choroidal Hemangioma","volume":"137","author":"Bichsel","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0021-9258(18)48452-9","article-title":"Recombinant Gq alpha. Mutational activation and coupling to receptors and phospholipase C","volume":"267","author":"Conklin","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1161\/ATVBAHA.121.316651","article-title":"Endothelial GNAQ p.R183Q Increases ANGPT2 (Angiopoietin-2) and Drives Formation of Enlarged Blood Vessels","volume":"42","author":"Huang","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2017.04.002","article-title":"RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma","volume":"31","author":"Chen","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry","volume":"25","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","article-title":"Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2509528122","DOI":"10.1073\/pnas.2509528122","article-title":"MAPK signaling and angiopoietin-2 contribute to endothelial permeability in capillary malformations","volume":"122","author":"Nasim","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10456-025-09986-4","article-title":"An endothelial specific mouse model for the capillary malformation mutation Gnaq p.R183Q","volume":"28","author":"Smits","year":"2025","journal-title":"Angiogenesis"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Nguyen, V., Hochman, M., Mihm, M.C., Nelson, J.S., and Tan, W. (2019). The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092243"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10456-022-09841-w","article-title":"A novel somatic mutation in GNAQ in a capillary malformation provides insight into molecular pathogenesis","volume":"25","author":"Galeffi","year":"2022","journal-title":"Angiogenesis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Bezrookove","year":"2009","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Griewank","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1167\/iovs.08-2145","article-title":"Oncogenic mutations in GNAQ occur early in uveal melanoma","volume":"49","author":"Onken","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2017.259","article-title":"GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi","volume":"117","author":"Vader","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ophtha.2018.12.011","article-title":"GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas","volume":"126","author":"Francis","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Le Guin, C.H.D., Metz, K.A., Kreis, S.H., Bechrakis, N.E., Bornfeld, N., Zeschnigk, M., and Lohmann, D.R. (2019). GNAQ Q209R Mutations Are Highly Specific for Circumscribed Choroidal Hemangioma. Cancers, 11.","DOI":"10.3390\/cancers11071031"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/pcmr.12843","article-title":"GNAQQ209L expression initiated in multipotent neural crest cells drives aggressive melanoma of the central nervous system","volume":"33","author":"Urtatiz","year":"2020","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/PAS.0000000000002127","article-title":"Papillary Hemangioma Harbors Somatic GNA11 and GNAQ Mutations","volume":"48","author":"Gestrich","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.ajhg.2024.05.020","article-title":"GNA14 and GNAQ somatic mutations cause spinal and intracranial extra-axial cavernous hemangiomas","volume":"111","author":"Ren","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0046-8177(00)80192-6","article-title":"GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas","volume":"31","author":"North","year":"2000","journal-title":"Hum. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/IOP.0b013e31828b0f1f","article-title":"Immunohistochemical investigations of orbital infantile hemangiomas and adult encapsulated cavernous venous lesions (malformation versus hemangioma)","volume":"29","author":"Osaki","year":"2013","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"Hoeger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0161-6420(78)35667-0","article-title":"The pathogenesis of glaucoma in Sturge-Weber syndrome","volume":"85","author":"Phelps","year":"1978","journal-title":"Ophthalmology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/bjophthalmol-2020-317287","article-title":"Somatic GNAQ R183Q mutation is located within the sclera and episclera in patients with Sturge-Weber syndrome","volume":"106","author":"Wu","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e23148","DOI":"10.1096\/fj.202300608R","article-title":"GNAQ R183Q somatic mutation contributes to aberrant arteriovenous specification in Sturge-Weber syndrome through Notch signaling","volume":"37","author":"Huang","year":"2023","journal-title":"FASEB J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40662-025-00432-6","article-title":"Sturge-Weber syndrome secondary glaucoma: From Pathogenesis to Treatment","volume":"12","author":"Wen","year":"2025","journal-title":"Eye Vis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.survophthal.2025.01.001","article-title":"Clinical features, diagnosis, management, and prognosis of circumscribed choroidal hemangioma","volume":"70","author":"Yang","year":"2025","journal-title":"Surv. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/13816810.2021.1910963","article-title":"Current concepts on diffuse choroidal hemangioma in Sturge Weber syndrome","volume":"42","author":"Formisano","year":"2021","journal-title":"Ophthalmic Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00417-023-06179-x","article-title":"New insights on circumscribed choroidal hemangioma: \u201cbench to bedside\u201d","volume":"262","author":"Lupidi","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10792-024-03238-y","article-title":"Management of circumscribed choroidal hemangioma at a tertiary care center","volume":"44","author":"Kiratli","year":"2024","journal-title":"Int. Ophthalmol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0092-8674(00)81814-0","article-title":"Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2","volume":"87","author":"Vikkula","year":"1996","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/ejhg.2009.193","article-title":"Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects","volume":"18","author":"Wouters","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/ng.272","article-title":"Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations","volume":"41","author":"Limaye","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000348327","article-title":"Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations","volume":"4","author":"Soblet","year":"2013","journal-title":"Mol. Syndromol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jid.2016.07.034","article-title":"Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations","volume":"137","author":"Soblet","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1093\/hmg\/ddt198","article-title":"Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB","volume":"22","author":"Uebelhoer","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"12352","DOI":"10.1038\/s41598-019-48854-2","article-title":"Constitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte Recruitment","volume":"9","author":"Cai","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1172\/JCI76004","article-title":"Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects","volume":"125","author":"Boscolo","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s44161-025-00655-9","article-title":"Angiopoietin-TIE2 feedforward circuit promotes PIK3CA-driven venous malformations","volume":"4","author":"Kraft","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ajhg.2015.11.011","article-title":"Somatic Activating PIK3CA Mutations Cause Venous Malformation","volume":"97","author":"Limaye","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.humpath.2024.02.004","article-title":"Comprehensive phenotypic and genomic characterization of venous malformations","volume":"145","author":"Hirose","year":"2024","journal-title":"Hum. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1048\u20131054.e1\u20135","DOI":"10.1016\/j.jpeds.2014.12.069","article-title":"Lymphatic and other vascular malformative\/overgrowth disorders are caused by somatic mutations in PIK3CA","volume":"166","author":"Luks","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13023-021-01898-y","article-title":"Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations","volume":"16","author":"Brouillard","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e74510","DOI":"10.7554\/eLife.74510","article-title":"Genomic landscape of lymphatic malformations: A case series and response to the PI3K\u03b1 inhibitor alpelisib in an N-of-1 clinical trial","volume":"11","author":"Shaheen","year":"2022","journal-title":"Elife"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Blesinger, H., Kaulfu\u00df, S., Aung, T., Schwoch, S., Prantl, L., R\u00f6\u00dfler, J., Wilting, J., and Becker, J. (2018). PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200343"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/gcc.22739","article-title":"Comprehensive molecular and clinicopathological analysis of vascular malformations: A study of 319 cases","volume":"58","author":"Eijkelenboom","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"a006147","DOI":"10.1101\/mcs.a006147","article-title":"Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in PIK3CA","volume":"7","author":"Sheppard","year":"2021","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Loy, K.A., Siu, J., Richardson, C., Perkins, J.N., Zenner, K., Koo, K., Perez, F., Bennett, J., Bly, R., and Hallam, D.K. (2026). Orbital Lymphatic Malformations Are Associated with Intracranial Vascular Anomalies. Laryngoscope, Online ahead of print.","DOI":"10.1002\/lary.70826"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/ng.2331","article-title":"De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes","volume":"44","author":"Mirzaa","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_75","first-page":"287","article-title":"PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation","volume":"167A","author":"Rios","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"87623","DOI":"10.1172\/jci.insight.87623","article-title":"PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution","volume":"1","author":"Mirzaa","year":"2016","journal-title":"JCI Insight"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/pde.13979","article-title":"Tufted angioma with associated Kasabach-Merritt phenomenon caused by somatic mutation in GNA14","volume":"36","author":"Lim","year":"2019","journal-title":"Pediatr. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/pin.12913","article-title":"Analysis of mTOR pathway expression in lymphatic malformation and related diseases","volume":"70","author":"Hori","year":"2020","journal-title":"Pathol. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10456-016-9537-2","article-title":"Angiopoietins as serum biomarkers for lymphatic anomalies","volume":"20","author":"Broering","year":"2017","journal-title":"Angiogenesis"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/labinvest.2013.98","article-title":"Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin","volume":"93","author":"Du","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0092-8674(00)81511-1","article-title":"Prox1 function is required for the development of the murine lymphatic system","volume":"98","author":"Wigle","year":"1999","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1038\/s41467-020-16496-y","article-title":"Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ajhg.2017.01.018","article-title":"Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation","volume":"100","author":"Couto","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1172\/JCI98589","article-title":"Mosaic RAS\/MAPK variants cause sporadic vascular malformations which respond to targeted therapy","volume":"128","author":"Polubothu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jdv.18046","article-title":"Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations","volume":"36","author":"Wassef","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Schmidt, V.F., Schanze, D., Brill, R., Loeser, J.H., Uller, W., Doppler, M., Cangir, \u00d6., Hengst, S., Vielsmeier, V., and Pech, M. (2026). Detection rate and mutational landscape in extracranial arteriovenous malformations: A cohort study. BMC Med., 24.","DOI":"10.1186\/s12916-026-04874-0"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jpedsurg.2023.01.047","article-title":"Genetic Profile of Arteriovenous Anomalies of the Head and Neck: Implications in Progression and Therapeutic Approaches","volume":"58","year":"2023","journal-title":"J. Pediatr. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00439-019-02072-y","article-title":"Arteriovenous malformation associated with a HRAS mutation","volume":"138","author":"Konczyk","year":"2019","journal-title":"Hum. Genet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10456-019-09678-w","article-title":"Intramuscular fast-flow vascular anomaly contains somatic MAP2K1 and KRAS mutations","volume":"22","author":"Goss","year":"2019","journal-title":"Angiogenesis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjd.20869","article-title":"Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway","volume":"186","author":"Maurus","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJMoa1709449","article-title":"Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain","volume":"378","author":"Nikolaev","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/1591019920982810","article-title":"KRAS\/BRAF mutations in brain arteriovenous malformations: A systematic review and meta-analysis","volume":"27","author":"Bameri","year":"2021","journal-title":"Interv. Neuroradiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/brain\/awy307","article-title":"High prevalence of KRAS\/BRAF somatic mutations in brain and spinal cord arteriovenous malformations","volume":"142","author":"Hong","year":"2019","journal-title":"Brain"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/CIRCRESAHA.119.316500","article-title":"Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling","volume":"127","author":"Fish","year":"2020","journal-title":"Circ. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10456-024-09918-8","article-title":"Somatic BrafV600E mutation in the cerebral endothelium induces brain arteriovenous malformations","volume":"27","author":"Tu","year":"2024","journal-title":"Angiogenesis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ana.26059","article-title":"Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice","volume":"89","author":"Park","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10456-022-09853-6","article-title":"Endothelial cell expression of mutant Map2k1 causes vascular malformations in mice","volume":"26","author":"Smits","year":"2023","journal-title":"Angiogenesis"},{"key":"ref_98","first-page":"e063","article-title":"MAP2K1 Mutation in Zebrafish Endothelial Cells Causes Arteriovenous Shunts Preventable by MEK Inhibition","volume":"4","author":"Sudduth","year":"2023","journal-title":"J. Vasc. Anom."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10456-024-09934-8","article-title":"Somatic RIT1 delins in arteriovenous malformations hyperactivate RAS-MAPK signaling amenable to MEK inhibition","volume":"27","author":"Kapp","year":"2024","journal-title":"Angiogenesis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10456-022-09836-7","article-title":"NRASQ61R mutation in human endothelial cells causes vascular malformations","volume":"25","author":"Boscolo","year":"2022","journal-title":"Angiogenesis"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2012-12-474601","article-title":"Endothelial RAF1\/ERK activation regulates arterial morphogenesis","volume":"121","author":"Deng","year":"2013","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1073\/pnas.0504391102","article-title":"Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice","volume":"102","author":"Carlson","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1086\/379793","article-title":"Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations","volume":"73","author":"Eerola","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/humu.22431","article-title":"RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation","volume":"34","author":"Revencu","year":"2013","journal-title":"Hum. Mutat."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/humu.20746","article-title":"Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations","volume":"29","author":"Revencu","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neuron.2018.11.041","article-title":"Mutations in Chromatin Modifier and Ephrin Signaling Genes in Vein of Galen Malformation","volume":"101","author":"Duran","year":"2019","journal-title":"Neuron"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/CIRCULATIONAHA.116.026886","article-title":"Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling","volume":"136","author":"Amyere","year":"2017","journal-title":"Circulation"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41436-019-0443-z","article-title":"Phenotype of CM-AVM2 caused by variants in EPHB4: How much overlap with hereditary hemorrhagic telangiectasia (HHT)?","volume":"21","author":"Akay","year":"2019","journal-title":"Genet. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmg.2017.10.004","article-title":"Somatic second hit mutation of RASA1 in vascular endothelial cells in capillary malformation-arteriovenous malformation","volume":"61","author":"Lapinski","year":"2018","journal-title":"Eur. J. Med. Genet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"a005256","DOI":"10.1101\/mcs.a005256","article-title":"Parkes Weber syndrome associated with two somatic pathogenic variants in RASA1","volume":"6","author":"Grimmer","year":"2020","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jmedgenet-2019-106024","article-title":"RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation","volume":"57","author":"Revencu","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ajpath.2014.08.018","article-title":"Blood vascular abnormalities in Rasa1(R780Q) knockin mice: Implications for the pathogenesis of capillary malformation-arteriovenous malformation","volume":"184","author":"Lubeck","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1172\/JCI124917","article-title":"RASA1-dependent cellular export of collagen IV controls blood and lymphatic vascular development","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCRESAHA.124.325383","article-title":"EPHB4-RASA1 Inhibition of PIEZO1 Ras Activation Drives Lymphatic Valvulogenesis","volume":"135","author":"Chen","year":"2024","journal-title":"Circ. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1073\/pnas.1222722110","article-title":"Lymphatic abnormalities are associated with RASA1 gene mutations in mouse and man","volume":"110","author":"Burrows","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1172\/JCI67084","article-title":"RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity","volume":"124","author":"Kawasaki","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41467-024-46300-0","article-title":"Eph-ephrin signaling couples endothelial cell sorting and arterial specification","volume":"15","author":"Stewen","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0300060513478091","article-title":"Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation","volume":"42","author":"Bai","year":"2014","journal-title":"J. Int. Med. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"dev201820","DOI":"10.1242\/dev.201820","article-title":"rasa1-related arteriovenous malformation is driven by aberrant venous signalling","volume":"150","author":"Rode","year":"2023","journal-title":"Development"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/JID.2015.376","article-title":"BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma","volume":"136","author":"Groesser","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"adv00715","DOI":"10.2340\/actadv.v102.1119","article-title":"Recurrent Alterations in the MAPK pathway in Sporadic Pyogenic Granuloma of Childhood","volume":"102","author":"Strobel","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/IOP.0000000000001075","article-title":"No BRAF V600E Mutation Identified in 28 Periocular Pyogenic Granuloma","volume":"34","author":"Li","year":"2018","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/jop.12922","article-title":"Oral pyogenic granulomas show MAPK\/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations","volume":"48","author":"Pereira","year":"2019","journal-title":"J. Oral Pathol. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/CMR.0000000000000248","article-title":"Pyogenic granuloma in patients treated with selective BRAF inhibitors: Another manifestation of paradoxical pathway activation","volume":"26","author":"Henning","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41390-022-01986-0","article-title":"Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition","volume":"94","author":"Chowers","year":"2023","journal-title":"Pediatr. Res."},{"key":"ref_126","first-page":"100028","article-title":"Cutaneous and hepatic vascular lesions due to a recurrent somatic GJA4 mutation reveal a pathway for vascular malformation","volume":"2","author":"Ugwu","year":"2021","journal-title":"HGG Adv."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/13815","article-title":"Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas","volume":"23","author":"Jung","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1086\/381718","article-title":"Mutations within the MGC4607 gene cause cerebral cavernous malformations","volume":"74","author":"Denier","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/426952","article-title":"Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations","volume":"76","author":"Bergametti","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/hmg\/ddn430","article-title":"Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): Evidence for a two-hit mechanism of CCM pathogenesis","volume":"18","author":"Akers","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature17178","article-title":"Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2\/4 signalling","volume":"532","author":"Zhou","year":"2016","journal-title":"Nature"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e20251374","DOI":"10.1084\/jem.20251374","article-title":"TIE2 links MEKK3-KLF2\/4 and PI3K signaling in cerebral cavernous malformation","volume":"223","author":"Li","year":"2026","journal-title":"J. Exp. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1038\/sj.onc.1203938","article-title":"Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function","volume":"19","author":"Krieg","year":"2000","journal-title":"Oncogene"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9440(10)65541-1","article-title":"Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF\/HIF-2alpha","volume":"153","author":"Flamme","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3892\/or.2015.3911","article-title":"Propranolol represses infantile hemangioma cell growth through the \u03b22-adrenergic receptor in a HIF-1\u03b1-dependent manner","volume":"33","author":"Li","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/svn-2022-002227","article-title":"Somatic GJA4 mutation in intracranial extra-axial cavernous hemangiomas","volume":"8","author":"Huo","year":"2023","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/01676830.2025.2515594","article-title":"Orbital angioleiomyoma with GJA4 mutation mimicking cavernous venous malformation: A case report and comprehensive review","volume":"44","author":"Callet","year":"2025","journal-title":"Orbit"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1038\/s41467-017-01742-7","article-title":"Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification","volume":"8","author":"Fang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1161\/ATVBAHA.119.313122","article-title":"Impaired SMAD1\/5 Mechanotransduction and Cx37 (Connexin37) Expression Enable Pathological Vessel Enlargement and Shunting","volume":"40","author":"Peacock","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/cac.10.4-6.379.385","article-title":"Role of connexin37 and connexin40 in vascular development","volume":"10","author":"Simon","year":"2003","journal-title":"Cell Commun. Adhes."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/IOP.0000000000002029","article-title":"Orbital Vascular Anomalies: A Nomenclatorial, Etiological, and Nosologic Conundrum","volume":"38","author":"Tawfik","year":"2022","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ajhg.2021.04.005","article-title":"Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation","volume":"108","author":"Weng","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41586-021-03562-8","article-title":"PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism","volume":"594","author":"Ren","year":"2021","journal-title":"Nature"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10456-023-09866-9","article-title":"Endothelial hyperactivation of mutant MAP3K3 induces cerebral cavernous malformation enhanced by PIK3CA GOF mutation","volume":"26","author":"Huo","year":"2023","journal-title":"Angiogenesis"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/WNO.0000000000000778","article-title":"Familial Cavernous Hemangioma","volume":"40","author":"Torres","year":"2020","journal-title":"J. Neuroophthalmol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Park, D.M., Zhuang, Z., Chen, L., Szerlip, N., Maric, I., Li, J., Sohn, T., Kim, S.H., Lubensky, I.A., and Vortmeyer, A.O. (2007). von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040060"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archopht.125.2.239","article-title":"Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis","volume":"125","author":"Wong","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e1492","DOI":"10.1111\/aos.14843","article-title":"Genotype-phenotype correlation in von Hippel-Lindau disease","volume":"99","author":"Reich","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Hwang, S., Kang, S.W., Kim, J.W., and Kim, S.J. (2024). Genotype-phenotype correlation of ocular von Hippel-Lindau disease in Koreans. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0311665"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e240260","DOI":"10.1530\/ERC-24-0260","article-title":"Genotype-specific neoplastic risk profiles in patients with VHL disease","volume":"32","author":"Ganner","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"104538","DOI":"10.1016\/j.ejmg.2022.104538","article-title":"von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance","volume":"65","author":"Binderup","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1097\/IAE.0000000000002572","article-title":"Management of retinal hemangioblastoma in von Hippel-Lindau disease","volume":"39","author":"Wiley","year":"2019","journal-title":"Retina"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ophtha.2024.05.024","article-title":"Oral Hypoxia-Inducible Factor 2\u03b1 Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study","volume":"131","author":"Wiley","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/sj.jid.5700516","article-title":"No evidence for maternal-fetal microchimerism in infantile hemangioma: A molecular genetic investigation","volume":"126","author":"Pittman","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jcp.2010.081257","article-title":"Haemogenic endothelium in infantile haemangioma","volume":"63","author":"Itinteang","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jclinpath-2011-200191","article-title":"A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma","volume":"64","author":"Itinteang","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1161\/ATVBAHA.107.150284","article-title":"Hypoxia-induced mediators of stem\/progenitor cell trafficking are increased in children with hemangioma","volume":"27","author":"Kleinman","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"Hubiche","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"258","DOI":"10.25259\/SNI_368_2024","article-title":"Orbital varices: Epidemiology, clinical presentation, and treatment outcomes\u2014A scoping review","volume":"15","author":"Kumar","year":"2024","journal-title":"Surg. Neurol. Int."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00417-006-0520-2","article-title":"Prevalence of ocular manifestations in hereditary hemorrhagic telangiectasia","volume":"245","author":"Geisthoff","year":"2007","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1002\/ccr3.8933","article-title":"Decades of stability of conjunctival vascular malformations in two patients","volume":"12","author":"Matsuo","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ajhg.2019.09.002","article-title":"Diagnostic Utility of Next-Generation Sequencing for Disorders of Somatic Mosaicism: A Five-Year Cumulative Cohort","volume":"105","author":"McNulty","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"ddaf169","DOI":"10.1093\/hmg\/ddaf169","article-title":"High depth targeted next-generation sequencing in vascular malformations","volume":"35","author":"Pakhathirathien","year":"2026","journal-title":"Hum. Mol. Genet."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"100815","DOI":"10.1016\/j.gimo.2023.100815","article-title":"Profiling PIK3CA variants in disorders of somatic mosaicism","volume":"1","author":"Mojarad","year":"2023","journal-title":"Genet. Med. Open"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41436-020-00943-8","article-title":"Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations","volume":"23","author":"Zenner","year":"2021","journal-title":"Genet. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/ajmg.a.63171","article-title":"High-depth next-generation sequencing panel testing in the evaluation of arteriovenous malformations","volume":"191","author":"Hernandez","year":"2023","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s43856-025-01174-1","article-title":"Harnessing liquid biopsy to unveil RAS-MEK pathway somatic pathogenic variants in extracranial arterio-venous malformations","volume":"5","author":"Bhatia","year":"2025","journal-title":"Commun. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40291-025-00770-0","article-title":"Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital","volume":"29","author":"Bisdorff","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-023-02364-x","article-title":"Genomic profiling informs diagnoses and treatment in vascular anomalies","volume":"29","author":"Li","year":"2023","journal-title":"Nat. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaad.2025.07.033","article-title":"Trametinib treatment for early-stage extracranial arteriovenous malformations: A multicenter, prospective, single-arm pilot study","volume":"93","author":"Sun","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamadermatol.2018.4653","article-title":"Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child","volume":"155","author":"Lekwuttikarn","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e64126","DOI":"10.1002\/ajmg.a.64126","article-title":"Multiple Genomic Technologies Validate Rare Novel Variant and Direct Medical Care in Vascular Anomalies","volume":"197","author":"Torales","year":"2025","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e173095","DOI":"10.1172\/jci.insight.173095","article-title":"Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations","volume":"8","author":"Seront","year":"2023","journal-title":"JCI Insight"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cge.14636","article-title":"Modified Rules for Classification of Variants Associated with Disorders of Somatic Mosaicism","volume":"107","author":"Bowling","year":"2025","journal-title":"Clin. Genet."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Gazzin, A., Leoni, C., Viscogliosi, G., Borgini, F., Perri, L., Iacoviello, M., Piglionica, M., De Pellegrin, M., Ferrero, G.B., and Bartuli, A. (2023). Work-Up and Treatment Strategies for Individuals with PIK3CA-Related Disorders: A Consensus of Experts from the Scientific Committee of the Italian Macrodactyly and PROS Association. Genes, 14.","DOI":"10.3390\/genes14122134"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11033-025-11371-9","article-title":"Ultra-deep targeted next-generation sequencing with peripheral blood in patients with vascular malformations: A cohort of 40 patients","volume":"53","author":"Mitamura","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13023-019-1191-5","article-title":"Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis","volume":"14","author":"Ozeki","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamaophthalmol.2016.0090","article-title":"Subretinal Fluid Associated with MEK Inhibitor Use in the Treatment of Systemic Cancer","volume":"134","author":"Weber","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"332ra43","DOI":"10.1126\/scitranslmed.aad9982","article-title":"Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans","volume":"8","author":"Castillo","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Rhein, K., Kotsis, F., Ganner, A., Astheimer, S., Gizaw, C.J., Laich, Y., Jilg, C.A., Klingler, J.H., and Neumann-Haefelin, E. (2025). Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors\u2014A retrospective single center analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15192-8"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"102011","DOI":"10.1016\/j.ajoc.2024.102011","article-title":"Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series","volume":"33","author":"Ercanbrack","year":"2024","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jamadermatol.2021.3459","article-title":"Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial","volume":"157","author":"Maruani","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/jdv.20385","article-title":"Long-term effects of sirolimus treatment for slow-flow vascular malformations: Real-world evidence from the French observational multicentre SIROLO study","volume":"39","author":"Maillet","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e28936","DOI":"10.1002\/pbc.28936","article-title":"Severe adverse events during sirolimus \u201coff-label\u201d therapy for vascular anomalies","volume":"68","author":"Baselga","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1346-8138.17688","article-title":"Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial","volume":"52","author":"Jinnin","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_191","first-page":"CD013000","article-title":"Interventions for orbital lymphangioma","volume":"5","author":"Patel","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/IOP.0000000000001518","article-title":"The Use of Sirolimus for Treatment of Orbital Lymphatic Malformations: A Systematic Review","volume":"36","author":"Shoji","year":"2020","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_193","first-page":"e71478","article-title":"Efficacy of Oral Sirolimus Therapy for Adult Orbital Slow-Flow Vascular Malformations: A Volumetric Evaluation","volume":"16","author":"Nomura","year":"2024","journal-title":"Cureus"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/01676830.2018.1436569","article-title":"Sirolimus-induced regression of a large orbital lymphangioma","volume":"38","author":"Joachimsen","year":"2019","journal-title":"Orbit"},{"key":"ref_195","unstructured":"Ain Shams University (2026, July 26). Systematic Approach for Children with Orbital Malformation with Sirolimus Use. ClinicalTrials.gov Identifier: NCT07378657, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07378657."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"eabg0809","DOI":"10.1126\/scitranslmed.abg0809","article-title":"Alpelisib administration reduced lymphatic malformations in a mouse model and in patients","volume":"13","author":"Delestre","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","article-title":"FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum","volume":"30","author":"Singh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1159\/000525772","article-title":"Bilateral Panuveitis and Exudative Retinal Detachments Associated with Alpelisib","volume":"15","author":"Chong","year":"2022","journal-title":"Case Rep. Oncol."},{"key":"ref_200","first-page":"100596","article-title":"Periorbital edema associated with alpelisib","volume":"32","author":"Dao","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/1078-0432.CCR-26-0149","article-title":"A phase 2 study of the MEK1\/2 inhibitor luvometinib in patients with extracranial arteriovenous malformations","volume":"32","author":"Hua","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Cucuruz, B., Deistung, A., Bidakov, O., Andercou, O., Schmitz-Rixen, T., Loeser, J., Inselmann, C., Koller, M., and Wohlgemuth, W.A. (2026). Trametinib for the treatment of advanced stage patients with arterio-venous malformations. Vasa, Online ahead of print.","DOI":"10.1024\/0301-1526\/a001286"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e155888","DOI":"10.1172\/jci.insight.155888","article-title":"Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition","volume":"8","author":"Sheppard","year":"2023","journal-title":"JCI Insight"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamadermatol.2021.0596","article-title":"Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial","volume":"157","author":"Puig","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaapos.2015.10.014","article-title":"Visual acuity and astigmatism in periocular infantile hemangiomas treated with oral beta-blocker versus intralesional corticosteroid injection","volume":"20","author":"Herlihy","year":"2016","journal-title":"J. AAPOS"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ijc.34509","article-title":"Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges","volume":"153","author":"Zhou","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","article-title":"MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects","volume":"65","author":"Urner","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: Incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","article-title":"Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database","volume":"128","author":"Mettler","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ophtha.2015.05.027","article-title":"Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma","volume":"122","author":"Marinkovic","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40264-022-01248-2","article-title":"Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies","volume":"45","author":"Barteselli","year":"2022","journal-title":"Drug Saf."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Lozano, L.P., Jennisch, M., Jensen, R., Ratcliff, J.A., Wiley, L.A., Harman, B., Riker, M.J., Wright, A.T., Erickson, B.A., and Boldt, H.C. (2025). Modeling MEK inhibitor-Associated Retinopathy in vitro using human induced pluripotent stem cell-derived retinal pigment epithelial cells. bioRxiv.","DOI":"10.1101\/2025.10.03.680301"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1177\/11206721221081471","article-title":"Choroidal vasculature analysis in MEK inhibitor-associated retinopathy","volume":"32","author":"Cerquaglia","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1758835920944359","DOI":"10.1177\/1758835920944359","article-title":"Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy","volume":"12","author":"Booth","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"104178","DOI":"10.1016\/j.jaapos.2025.104178","article-title":"Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases","volume":"29","author":"Liu","year":"2025","journal-title":"J. AAPOS"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"104157","DOI":"10.1016\/j.jaapos.2025.104157","article-title":"Baseline ophthalmic findings and complications in pediatric patients treated with MEK inhibitors","volume":"29","author":"Hazariwala","year":"2025","journal-title":"J. AAPOS"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3390\/curroncol31050199","article-title":"Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors","volume":"31","author":"Hummel","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/08820538.2025.2468381","article-title":"Incidence and Management of Retinopathy and Uveitis in Patients Receiving BRAF\/MEK Inhibitor Therapy","volume":"40","author":"Nakajima","year":"2025","journal-title":"Semin. Ophthalmol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","article-title":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","volume":"144","author":"Dimitriou","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_222","first-page":"1224","article-title":"Ophthalmic adverse effects of BRAF inhibitors","volume":"33","author":"Smith","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000501155","article-title":"MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants","volume":"6","author":"Francis","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.oret.2021.06.001","article-title":"Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy","volume":"5","author":"Francis","year":"2021","journal-title":"Ophthalmol. Retin."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"e29897","DOI":"10.1002\/pbc.29897","article-title":"Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: Preliminary pharmacokinetics and pharmacodynamic data","volume":"69","author":"Remy","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13023-025-03831-z","article-title":"Safety findings from the phase 1\/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome","volume":"20","author":"Eng","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jaad.2014.10.011","article-title":"Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: Phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial","volume":"72","author":"Aguado","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1111\/jocd.13867","article-title":"Evaluating the efficacy and safety of topical sirolimus 0.2% cream as adjuvant therapy with pulsed dye laser for the treatment of port wine stain: A randomized, double-blind, placebo-controlled trial","volume":"20","author":"Fallahi","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pediatrneurol.2020.10.013","article-title":"Sirolimus Treatment in Sturge-Weber Syndrome","volume":"115","author":"Sebold","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(22)00409-4","article-title":"Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): A randomised, open-label, blinded-endpoint, phase 2 pilot trial","volume":"22","author":"Lanfranconi","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s12015-025-10984-8","article-title":"Vascular Organoids Derived from Capillary malformation-induced Pluripotent Stem Cells Exhibit Disease-Relevant Phenotypes","volume":"22","author":"Nguyen","year":"2026","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.stem.2024.10.015","article-title":"Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery","volume":"32","author":"Pan","year":"2025","journal-title":"Cell Stem Cell"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e20240513","DOI":"10.1084\/jem.20240513","article-title":"A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA)","volume":"222","author":"Bassi","year":"2025","journal-title":"J. Exp. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e179729","DOI":"10.1172\/jci.insight.179729","article-title":"CRISPR\/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice","volume":"9","author":"Saito","year":"2024","journal-title":"JCI Insight"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/11206721251378581","article-title":"Quantitative analysis of the anti-VEGF effect for retinal capillary hemangiomas and vasoproliferative tumors","volume":"36","author":"Fang","year":"2026","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Chou, H.D., Downie, C., Anguita, R., Negretti, G.S., and Sagoo, M.S. (2026). Sandwich therapy combining photodynamic therapy and adjunctive anti-VEGF for juxtapapillary retinal capillary hemangioblastoma. Graefes Arch. Clin. Exp. Ophthalmol., Online ahead of print.","DOI":"10.1007\/s00417-026-07323-z"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8244\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:09:31Z","timestamp":1789549771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":236,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188244"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188244","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}